CD31+ Cell Isolation for Regenerative Medicine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for selecting and isolating stem cells for regenerative medicine are inadequate, particularly for cardiovascular regeneration, due to issues such as adverse effects from unfractionated bone marrow cells, low numbers of CD34+ or c-kit+ cells, and the need for large serum quantities and long culture times for endothelial progenitor cells.
Innovation Solution
The use of CD31+ cells, which can differentiate into endothelial cells and secrete paracrine factors, for tissue repair and angiogenesis, including methods for isolating and culturing these cells from bone marrow, peripheral blood, or umbilical cord blood, and administering them to regenerate tissues affected by ischemia or neuropathy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If unfractionated whole bone marrow cells are used for tissue regeneration, then the therapeutic effect is achieved, but adverse effects such as intramyocardial calcification occur
Solution Approach 1:
The patent extracts and isolates specific CD34+ stem cells from the complex bone marrow cell population, separating the beneficial regenerative components from the harmful elements that cause adverse effects like calcification. This selective extraction allows therapeutic application without the side effects of unfractionated bone marrow cells.
Solution Approach 2:
The patent applies local quality by using specifically identified CD34+ cells with particular properties for different therapeutic applications. Different cell subsets with distinct characteristics can be selected for specific tissue regeneration needs, optimizing therapeutic effect while minimizing adverse reactions in different tissue contexts.
2Reliability
If CD34+ cells are used for tissue regeneration, then the therapeutic effect is improved, but the cell numbers are too low requiring mobilization processes
Solution Approach 1:
The patent employs preliminary action by using mobilization protocols before cell collection to increase the number of CD34+ cells available in peripheral blood. This preparatory step ensures sufficient cell quantities are obtained for therapeutic applications without compromising cell quality or therapeutic effectiveness.
3Productivity
If endothelial progenitor cells are used for tissue regeneration, then the cells are culture expandable, but large amounts of serum are required and culture time is prolonged
Solution Approach 1:
The patent applies parameter changes by optimizing culture conditions including serum-free or reduced-serum media formulations, growth factor concentrations, and culture protocol parameters. These parameter modifications enable efficient cell expansion without requiring large amounts of serum, reducing cost and preparation time while maintaining cell quality.
4Productivity
If endothelial progenitor cells are used for tissue regeneration, then the cells can be cultured, but the preparation time is extended from days to months
Solution Approach 1:
The patent optimizes culture parameters including medium composition, growth factors, cell seeding density, and incubation conditions to accelerate cell proliferation rates. These parameter changes reduce the culture time from months to days or weeks, enabling faster cell preparation for clinical applications while maintaining adequate cell numbers and quality.
Data Source
AI summary
The present invention features compositions and methods related to the isolation, culture and therapeutic use of CD31-expressing cells.